353 related articles for article (PubMed ID: 36278695)
1. Proteomics-Based Identification of Dysregulated Proteins in Breast Cancer.
Neagu AN; Jayathirtha M; Whitham D; Mutsengi P; Sullivan I; Petre BA; Darie CC
Proteomes; 2022 Oct; 10(4):. PubMed ID: 36278695
[TBL] [Abstract][Full Text] [Related]
2. Proteomics-Based Identification of Dysregulated Proteins and Biomarker Discovery in Invasive Ductal Carcinoma, the Most Common Breast Cancer Subtype.
Neagu AN; Whitham D; Seymour L; Haaker N; Pelkey I; Darie CC
Proteomes; 2023 Apr; 11(2):. PubMed ID: 37092454
[TBL] [Abstract][Full Text] [Related]
3. Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer.
Suman S; Basak T; Gupta P; Mishra S; Kumar V; Sengupta S; Shukla Y
J Proteomics; 2016 Oct; 148():183-93. PubMed ID: 27498393
[TBL] [Abstract][Full Text] [Related]
4. High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.
Terkelsen T; Pernemalm M; Gromov P; Børresen-Dale AL; Krogh A; Haakensen VD; Lethiö J; Papaleo E; Gromova I
Mol Oncol; 2021 Feb; 15(2):429-461. PubMed ID: 33176066
[TBL] [Abstract][Full Text] [Related]
5. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
[TBL] [Abstract][Full Text] [Related]
6. Proteomics and its applications in breast cancer.
Neagu AN; Whitham D; Buonanno E; Jenkins A; Alexa-Stratulat T; Tamba BI; Darie CC
Am J Cancer Res; 2021; 11(9):4006-4049. PubMed ID: 34659875
[TBL] [Abstract][Full Text] [Related]
7. MASH Suite Pro: A Comprehensive Software Tool for Top-Down Proteomics.
Cai W; Guner H; Gregorich ZR; Chen AJ; Ayaz-Guner S; Peng Y; Valeja SG; Liu X; Ge Y
Mol Cell Proteomics; 2016 Feb; 15(2):703-14. PubMed ID: 26598644
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer.
Orfanou IM; Argyros O; Papapetropoulos A; Tseleni-Balafouta S; Vougas K; Tamvakopoulos C
Front Oncol; 2021; 11():608201. PubMed ID: 33842315
[TBL] [Abstract][Full Text] [Related]
9. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
[TBL] [Abstract][Full Text] [Related]
10. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes.
Gajbhiye A; Dabhi R; Taunk K; Jagadeeshaprasad MG; RoyChoudhury S; Mane A; Bayatigeri S; Chaudhury K; Santra MK; Rapole S
J Proteomics; 2017 Jun; 163():1-13. PubMed ID: 28495502
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Unknown Posttranslational Modifications by Top-Down Mass Spectrometry.
Wilson JW; Zhou M
Methods Mol Biol; 2022; 2500():181-199. PubMed ID: 35657594
[TBL] [Abstract][Full Text] [Related]
12. Top Down Proteomics Reveals Mature Proteoforms Expressed in Subcellular Fractions of the Echinococcus granulosus Preadult Stage.
Lorenzatto KR; Kim K; Ntai I; Paludo GP; Camargo de Lima J; Thomas PM; Kelleher NL; Ferreira HB
J Proteome Res; 2015 Nov; 14(11):4805-14. PubMed ID: 26465659
[TBL] [Abstract][Full Text] [Related]
13. Improving Proteoform Identifications in Complex Systems Through Integration of Bottom-Up and Top-Down Data.
Schaffer LV; Millikin RJ; Shortreed MR; Scalf M; Smith LM
J Proteome Res; 2020 Aug; 19(8):3510-3517. PubMed ID: 32584579
[TBL] [Abstract][Full Text] [Related]
14. High-resolution ultrahigh-pressure long column reversed-phase liquid chromatography for top-down proteomics.
Shen Y; Tolić N; Piehowski PD; Shukla AK; Kim S; Zhao R; Qu Y; Robinson E; Smith RD; Paša-Tolić L
J Chromatogr A; 2017 May; 1498():99-110. PubMed ID: 28077236
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Human Sperm Protamine Proteoforms through a Combination of Top-Down and Bottom-Up Mass Spectrometry Approaches.
Soler-Ventura A; Gay M; Jodar M; Vilanova M; Castillo J; Arauz-Garofalo G; Villarreal L; Ballescà JL; Vilaseca M; Oliva R
J Proteome Res; 2020 Jan; 19(1):221-237. PubMed ID: 31703166
[TBL] [Abstract][Full Text] [Related]
16. Multidimensional separation schemes enhance the identification and molecular characterization of low molecular weight proteomes and short open reading frame-encoded peptides in top-down proteomics.
Cassidy L; Helbig AO; Kaulich PT; Weidenbach K; Schmitz RA; Tholey A
J Proteomics; 2021 Jan; 230():103988. PubMed ID: 32949814
[TBL] [Abstract][Full Text] [Related]
17. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
18. Molecular insights into cancer drug resistance from a proteomics perspective.
An Y; Zhou L; Huang Z; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2019 May; 16(5):413-429. PubMed ID: 30925852
[TBL] [Abstract][Full Text] [Related]
19. Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis.
Gan S; Dai H; Li R; Liu W; Ye R; Ha Y; Di X; Hu W; Zhang Z; Sun Y
Gland Surg; 2020 Jun; 9(3):661-675. PubMed ID: 32775256
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
